EP2367543A2 - 5-ht2a und 5-ht2b rezeptorantagonisten zur behandlung der spinalkanalstenose - Google Patents

5-ht2a und 5-ht2b rezeptorantagonisten zur behandlung der spinalkanalstenose

Info

Publication number
EP2367543A2
EP2367543A2 EP09795786A EP09795786A EP2367543A2 EP 2367543 A2 EP2367543 A2 EP 2367543A2 EP 09795786 A EP09795786 A EP 09795786A EP 09795786 A EP09795786 A EP 09795786A EP 2367543 A2 EP2367543 A2 EP 2367543A2
Authority
EP
European Patent Office
Prior art keywords
patients
group
stenosis
spinal
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09795786A
Other languages
German (de)
English (en)
French (fr)
Inventor
Rudolf Reiter
Lothar Pache
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to EP09795786A priority Critical patent/EP2367543A2/de
Publication of EP2367543A2 publication Critical patent/EP2367543A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • this serves for the prophylactic treatment of patients with spinal canal stenosis and the symptoms caused thereby in these patients for the prevention of the chronification of the symptoms complex
  • NSAIDs examples include sasapyrins, sodium salicylaf, aspirin, aspirin dialuminate, diflunisal, indomethacin, suprofen, ufenamate, dimethylisopropylazulen, bufexamac, felbinac, diclofenac, tolmetinin, clinoril, fenbufen, nabumetone, proglumetacin, indomethacin-farnesyl, acemetacin, proglumetacin maleate, amfenac sodium, mofezolac, etodolac, ibuprofen, ibuprofen-piconol, naproxen, flurbiprofen, flurbiprofenaxetil, ketoprofen, fenoprofen-calcium, tiaprofenic acid, oxaprozin, pranoprofen, loxoprofen-natrium,
  • the present invention further relates to the compounds of the formula

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
EP09795786A 2008-12-23 2009-12-22 5-ht2a und 5-ht2b rezeptorantagonisten zur behandlung der spinalkanalstenose Withdrawn EP2367543A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09795786A EP2367543A2 (de) 2008-12-23 2009-12-22 5-ht2a und 5-ht2b rezeptorantagonisten zur behandlung der spinalkanalstenose

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08172859 2008-12-23
EP09795786A EP2367543A2 (de) 2008-12-23 2009-12-22 5-ht2a und 5-ht2b rezeptorantagonisten zur behandlung der spinalkanalstenose
PCT/EP2009/067768 WO2010072774A2 (de) 2008-12-23 2009-12-22 Mittel zur behandlung der spinalkanalstenose

Publications (1)

Publication Number Publication Date
EP2367543A2 true EP2367543A2 (de) 2011-09-28

Family

ID=40527906

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09795786A Withdrawn EP2367543A2 (de) 2008-12-23 2009-12-22 5-ht2a und 5-ht2b rezeptorantagonisten zur behandlung der spinalkanalstenose

Country Status (11)

Country Link
EP (1) EP2367543A2 (pt)
JP (1) JP2012513446A (pt)
KR (1) KR20110098965A (pt)
CN (1) CN102271667A (pt)
AU (1) AU2009331469A1 (pt)
BR (1) BRPI0923556A2 (pt)
CA (1) CA2748163A1 (pt)
IL (1) IL213768A0 (pt)
MX (1) MX2011006852A (pt)
SG (1) SG172315A1 (pt)
WO (1) WO2010072774A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009405A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo ergolina y usos de estos.
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69919191T2 (de) 1998-09-01 2005-07-28 Nissan Chemical Industries, Ltd. Heilmittel für die stenose des rückenmarkkanals
WO2004043491A1 (ja) 2002-11-14 2004-05-27 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
US20070167403A1 (en) 2003-04-03 2007-07-19 Yoshifumi Takenobu Remedy for spinal canal stenosis
DE102006013307B3 (de) 2006-03-21 2007-10-04 Ergonex Pharma Gmbh Tergurid/Protergurid zur Behandlung von chronischen Schmerzen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010072774A2 *

Also Published As

Publication number Publication date
KR20110098965A (ko) 2011-09-02
MX2011006852A (es) 2011-07-20
AU2009331469A1 (en) 2011-07-21
BRPI0923556A2 (pt) 2016-01-26
IL213768A0 (en) 2011-07-31
WO2010072774A3 (de) 2010-09-23
JP2012513446A (ja) 2012-06-14
WO2010072774A2 (de) 2010-07-01
SG172315A1 (en) 2011-07-28
CN102271667A (zh) 2011-12-07
CA2748163A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
TWI314054B (en) Novel methods and compositions for alleviating pain
JP5663699B2 (ja) ピラゾール誘導体及びその医薬用途
Coderre et al. Effects of peripheral antisympathetic treatments in the tail-flick, formalin and autotomy tests
DE69430232T2 (de) Hemmung der Symptome des prämenstruellen Synchroms/dysphorische Erkrankungen der späten lutealen Phase
WO2007045620A1 (de) Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls)
EA007532B1 (ru) Новое применение харкосерида и его производных для лечения боли, не связанной с невропатическим воспалением
HUP0400505A2 (hu) Gaba-receptorra ható vegyületek alkalmazása csökkent neuroszteroid aktivitás kezelésére alkalmas gyógyászati készítmények előállítására
US12128012B2 (en) Ketamine treatment for amyotrophic lateral sclerosis
RU2290929C2 (ru) Фармацевтическая композиция для лечения интерстициального цистита
EP0752246A2 (de) Kappa-Opiate für entzündliche Darmerkrankungen
WO2013035712A1 (ja) 筋萎縮性側索硬化症の治療又は病勢進展抑制のための薬剤
HK1218079A1 (zh) 亞硝酸鹽的藥物製劑及其用途
DE2823174A1 (de) Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose
Hennies A New Skeletal Muscle Relaxant (DS 103-282*) Compared to Diazepam in the Treatment of Muscle Spasm of Local Origin
JPH09323927A (ja) 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤
TWI334780B (en) Method of treating movement disorders using barbituric acid derivatives
EP2367543A2 (de) 5-ht2a und 5-ht2b rezeptorantagonisten zur behandlung der spinalkanalstenose
DE69812028T2 (de) Creatine Derivate für Asthma
JP5908072B2 (ja) 腹圧性尿失禁予防剤及び／又は治療剤
BR112020009265A2 (pt) medicamento e composição farmacêutica para a prevenção, alívio ou tratamento de crise de ausência ou epilepsia que apresenta crise de ausência, uso de um composto de carbamato ou um sal, solvato ou hidrato do mesmo, e, método para prevenir, aliviar ou tratar crise de ausência ou epilepsia que apresenta crise de ausência.
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
MXPA06006685A (es) Uso de gaboxadol para tratar el insomnio.
EP3711756A1 (en) Use of carbamate compound for preventing, alleviating or treating myotonia
WO2020257336A1 (en) Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
WO1998005207A1 (en) Method for treating excessive aggression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110330

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120212